• Mutation; HGNC; 1787; CDKN2A; Simple; p.His83Tyr (c.247C>T) (p.Ala97Val, c.290C>T); ClinVar=VCV000376307; Zygosity=Unspecified (from autologous cell line NCI-H157).
  
• Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Arg (c.34G>C); ClinVar=VCV000012579; Zygosity=Unspecified (PubMed=1311061; PubMed=12068308).
  
• Mutation; HGNC; 11998; TP53; Simple; p.Glu298Ter (c.892G>T); ClinVar=VCV000093323; Zygosity=Unspecified (PubMed=1311061).
  

PubMed=1311061
Mitsudomi T., Steinberg S.M., Nau M.M., Carbone D.P., D'Amico D., Bodner S.M., Oie H.K., Linnoila R.I., Mulshine J.L., Minna J.D., Gazdar A.F.
p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features.
Oncogene 7:171-180(1992)

PubMed=1563005
Giaccone G., Battey J., Gazdar A.F., Oie H.K., Draoui M., Moody T.W.
Neuromedin B is present in lung cancer cell lines.
Cancer Res. 52:2732s-2736s(1992)

PubMed=8806092; DOI=10.1002/jcb.240630505
Phelps R.M., Johnson B.E., Ihde D.C., Gazdar A.F., Carbone D.P., McClintock P.R., Linnoila R.I., Matthews M.J., Bunn P.A. Jr., Carney D.N., Minna J.D., Mulshine J.L.
NCI-Navy Medical Oncology Branch cell line data base.
J. Cell. Biochem. Suppl. 24:32-91(1996)

PubMed=9649128; DOI=10.1038/bjc.1998.361; PMCID=PMC2150402
Yi S., Chen J.-R., Viallet J., Schwall R.H., Nakamura T., Tsao M.-S.
Paracrine effects of hepatocyte growth factor/scatter factor on non-small-cell lung carcinoma cell lines.
Br. J. Cancer 77:2162-2170(1998)

PubMed=11030152; DOI=10.1038/sj.onc.1203815
Modi S., Kubo A., Oie H.K., Coxon A.B., Rehmatulla A., Kaye F.J.
Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.
Oncogene 19:4632-4639(2000)

PubMed=11369051; DOI=10.1016/S0165-4608(00)00363-0
Luk C., Tsao M.-S., Bayani J., Shepherd F.A., Squire J.A.
Molecular cytogenetic analysis of non-small cell lung carcinoma by spectral karyotyping and comparative genomic hybridization.
Cancer Genet. Cytogenet. 125:87-99(2001)

PubMed=12068308; DOI=10.1038/nature00766
Davies H.R., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S., Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S., Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.
Mutations of the BRAF gene in human cancer.
Nature 417:949-954(2002)

PubMed=31803961; DOI=10.1002/jcb.29564; PMCID=PMC7496084
Mulshine J.L., Ujhazy P., Antman M., Burgess C.M., Kuzmin I.A., Bunn P.A. Jr., Johnson B.E., Roth J.A., Pass H.I., Ross S.M., Aldige C.R., Wistuba I.I., Minna J.D.
From clinical specimens to human cancer preclinical models -- a journey the NCI-cell line database-25 years later.
J. Cell. Biochem. 121:3986-3999(2020)